Overview
ICON plc provides clinical research outsourcing services for biotech and small to mid-sized biopharma companies. It supports programs from early-phase design through market access, and offers consulting, advisory services, and tailored clinical development. The company also focuses on areas such as genomic breakthroughs, first-in-class immunotherapies, and drug development in APAC and China.
Financials
The financial statement for 2024 has not yet been filed with the Financial Document Repository (past deadline).
Revenue history (in m)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2023.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2001-12-04. Active
27 1030 1508 0000 0008 2416 4836- 66 1030 1508 0000 0008 2416 4328
07 1140 1977 0000 2292 5600 1002
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| May 7, 2024 | Commercial Companies Code notice | |
| Nov 21, 2019 | Financial statement published | |
| Aug 1, 2018 | Bankruptcy notice | |
| Nov 17, 2014 | Bankruptcy notice | |
| Nov 3, 2014 | Financial statement published |
Public aid
No public aid cases recorded in the last 10 years.
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2010-07-01 | Health-f2-2010-261358/paddington | $1,772,643 | FP7 Cooperation |
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
Each member of the management board is authorized to make declarations of will on behalf of the company independently.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Simon Hollywood (46)  | Natural person holding a senior management position (AML Act art. 2(2)(1)(a) indent 5). |
Simon Holmes (60) | Natural person holding a senior management position (AML Act art. 2(2)(1)(a) indent 5). |
Emer Lyons (48) | Natural person holding a senior management position (AML Act art. 2(2)(1)(a) indent 5). |
Subsidiaries
| Name | Share value | Stake | |
|---|---|---|---|
Curandussp. z o.o. | 13,506.21 USD | 100% | |
KCR Placementsp. z o.o. | 13,506.21 USD | 100% |
Competitors
Selected automatically: mainly by similarity of the business description, plus comparable revenue, industry (PKD code) and location. Only companies with a complete profile (including a logo and financial data) are shown. The list is indicative.
| Name | Revenue | Website | |
|---|---|---|---|
| Polpharma BiologicsS.A. | $19,057,541.37 | polpharmabiologics.com | |
| ArdigenS.A. | $12,513,309.89 | ardigen.com | |
| Sidlysp. z o.o. | $4,977,649.42 | sidly.eu |
Change history
| Date | Event |
|---|---|
| 2025-04-28 | Address change (Postępu 6, 02-676, Warszawa → Ul. Prosta 68, 00-838, Warszawa) |
| 2025-04-28 | PKD change (Removed: 46.46.Z, 69.20.Z, 70.10.Z, 70.21.Z, 70.22.Z, 72.19.Z, 73.20.Z, 82.30.Z, 85.60.Z, 86.90.E; Added: 69.20.A, 69.20.B, 70.10.B, 70.20.Z, 72.10.Z, 73.30.B) |
| 2024-07-18 | Share capital change (571,666.20 PLN → 506,246.20 PLN) |
| 2018-05-21 | Share capital change (700,000.00 PLN → 571,666.20 PLN) |
| 2015-01-12 | PKD change (Removed: 46.18.Z, 46.19.Z, 85.59.B) |
FAQ
Last updated: 2026-03-22